BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9379442)

  • 21. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
    Wilkinson JD; Williamson EM
    J Dermatol Sci; 2007 Feb; 45(2):87-92. PubMed ID: 17157480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.
    Hou DR; Alam S; Kuan TC; Ramanathan M; Lin TP; Hung MS
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1022-5. PubMed ID: 19095444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
    Marriott KS; Huffman JW; Wiley JL; Martin BR
    Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
    Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
    J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
    Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
    Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation.
    Bouaboula M; Desnoyer N; Carayon P; Combes T; Casellas P
    Mol Pharmacol; 1999 Mar; 55(3):473-80. PubMed ID: 10051530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
    Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR
    Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors.
    Hanus LO; Tchilibon S; Ponde DE; Breuer A; Fride E; Mechoulam R
    Org Biomol Chem; 2005 Mar; 3(6):1116-23. PubMed ID: 15750656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only.
    Fride E; Feigin C; Ponde DE; Breuer A; Hanus L; Arshavsky N; Mechoulam R
    Eur J Pharmacol; 2004 Dec; 506(2):179-88. PubMed ID: 15588739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.
    MacLennan SJ; Reynen PH; Kwan J; Bonhaus DW
    Br J Pharmacol; 1998 Jun; 124(4):619-22. PubMed ID: 9690851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor.
    Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM
    Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
    Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
    FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of cannabinoid receptors.
    Howlett AC
    Annu Rev Pharmacol Toxicol; 1995; 35():607-34. PubMed ID: 7598509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.
    Compton DR; Rice KC; De Costa BR; Razdan RK; Melvin LS; Johnson MR; Martin BR
    J Pharmacol Exp Ther; 1993 Apr; 265(1):218-26. PubMed ID: 8474008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model.
    Howlett AC; Johnson MR; Melvin LS; Milne GM
    Mol Pharmacol; 1988 Mar; 33(3):297-302. PubMed ID: 3352594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
    Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
    J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
    Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
    J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enantiomeric resolution of a novel chiral cannabinoid receptor ligand.
    Thakur GA; Palmer SL; Harrington PE; Stergiades IA; Tius MA; Makriyannis A
    J Biochem Biophys Methods; 2002 Dec; 54(1-3):415-22. PubMed ID: 12543516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.